Magdalini Sachana

Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence

Richard A. Becker, Gerald T. Ankley, Stephen W. Edwards et al. · Regulatory Toxicology and Pharmacology · 2015 · 259 citations · Full text

Pharmacy, Risk Management, Evidence-based Practice +15

Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods

Anna Bal‐Price, Francesca Pistollato, Magdalini Sachana et al. · Toxicology and Applied Pharmacology · 2018 · 151 citations · Full text

Pharmacy, Toxicology, Developmental Toxicology +16

Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes

Ellen Fritsche, Philippe Grandjean, Kevin M. Crofton et al. · Toxicology and Applied Pharmacology · 2018 · 122 citations · Full text

Pharmacy, Neuroscience, Toxicology +17

Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology

Joshua Harrill, Mark R. Viant, Carole L. Yauk et al. · Regulatory Toxicology and Pharmacology · 2021 · 93 citations · Full text

Life Sciences, Toxicology, Metabolomics +15

International Regulatory and Scientific Effort for Improved Developmental Neurotoxicity Testing

Magdalini Sachana, Anna Bal‐Price, Kevin M. Crofton et al. · Toxicological Sciences · 2018 · 75 citations

Pharmacy, Toxicology, Developmental Toxicology +16